Kristin Kantautas

Founder & CEO @metabolisbio | Creator of

[Kristin Kantautas @kkantaut]

Rare disease drug development has a math problem.

One drug. One disease. $1B+. 10+ years.

That math doesn't work for 1500+ rare metabolic diseases. The proof: 80% still have no treatment.

At @PerlaraPBC & Cure SRD5A3 I’ve spent 6 years discovering and developing medicines for rare diseases. The TradBio model doesn't work for rare.

My takeaway: many rare metabolic diseases break down at the same hubs in metabolism.

Target the hub. Treat many diseases with a single medicine.

Today I'm announcing @Metabolisbio. A biotech built with my co-founder @eperlste to develop keystone medicines: a new class of treatments for rare metabolic diseases.

We discover naturally occurring metabolites and develop them into medicines that can treat many rare diseases.

We also run AI-powered at-home patient studies. Faster data. Lower cost. No traveling to a trial site.

Our first program is NMN for DHDDS-CDG. A pediatric neurodegenerative disease.

NMN has already shown it can slow disease progression in patients. Read the preprint: https://t.co/KVD7uAq1DQ

We're raising a pre-seed round. If you believe rare disease is the proving ground for the next generation of metabolic medicines let's talk.

https://t.co/oh4bvl7YcI

[Kristin Kantautas @kkantaut]

We're raising a pre-seed round.

If you believe rare disease is the proving ground for the next generation of metabolic medicines, let's talk.

https://t.co/vfnJD9cEDB

[Kristin Kantautas @kkantaut]

Our first program is NMN for DHDDS-CDG. A pediatric neurodegenerative disease.

NMN has already shown it can slow disease progression in patients.

Read the preprint: https://t.co/rj5I9mJO5O

[Kristin Kantautas @kkantaut]

We also run AI-powered at-home patient studies.

Faster data. Lower cost. No traveling to a trial site.

[Kristin Kantautas @kkantaut]

We discover naturally occurring metabolites and develop them into medicines that can treat many rare diseases.

[Kristin Kantautas @kkantaut]

Today I'm announcing @Metabolisbio. Abiotech built with my co-founder @eperlste to develop keystone medicines: a new class of treatments for rare metabolic diseases.

[Cure SRD5A3 @CureSrd5a3]

Today is World Congenital Disorders of #Glycosylation Awareness Day #WorldCDGDay

To raise awareness & celebrate our wonderful community - we put together a report on SRD5A3-CDG & the ongoing research at Cure SRD5A3!

Read it here
https://t.co/beFD6jpLhQ

#StandUnited4CDG

[Kristin Kantautas @kkantaut]

@sanathkr_ Congrats, incredible work!

[Kristin Kantautas @kkantaut]

@Mom2EmAndTy Laura, I am so very sorry for your loss. Emily was such a bright light I will always remember her laughter, hugs and wonderful spirit. Sending you and your family love during this difficult time

[Kristin Kantautas @kkantaut]

@IStedman @yorkuniversity @YorkUSPPA Amazing! Congrats Ian!

[Kristin Kantautas @kkantaut]

@TraverHart @MedinaColic1 Excellent! Congrats!

[Ethan Perlstein 1-to-N @eperlste]

Inspiring profile of #NGLY1 super-advocate @mattmight and all that he’s done for his family, the #NGLY1 community, and the rare community writ large.
https://t.co/VofGJZpPSz

[Kristin Kantautas @kkantaut]

@Michael_Aregger @DonnellyCentre @spaiglass @UofT Congrats Michael!

[rareDIG @McGill_rareDIG]

@rareDIG_TO founders @wolfeofscience and @scienceoframen present "using CRISPR to unravel gene networks in rare disorders" #RareDialogue2019 @raredisorders

[Kristin Kantautas @kkantaut]

@TraverHart Had to be done!